Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions,
rewards, and special promotions.
Unfortunately, the antibody (ID:41035) is no longer available.
Below is a list of antibodies to the same protein target. You may also try your search again using the search box at the top of the page.
Please contact us if you have any questions.
MCL1 / MCL 1
myeloid cell leukemia sequence 1 (BCL2-related)
Myeloid cell leukimia-1 (Mcl-1) is a member of the Bcl-2 family of proteins that can act to promote cell survival. While the mechanism by which Mcl-1 inhibits apoptosis is not known, it is thought that it may heterodimerize and neutralize pro-apoptotic members of the Bcl-2 family such as Bim or Bak. Mcl-1 was originally identified in differentiating myeloid cells, but has since been shown to be expressed in multiple cell types. Mcl-1 is essential for embryogenesis (5) and for the development and maintenance of B and T lymphocytes in animals. Mcl-1 exists as at least two distinct isoforms designated Mcl-1L and Mcl-1S. In marked contrast to the larger isoform of Mcl-1, overexpression of Mcl-1S promotes cell death.
Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Zhao Y, Altman BJ, Coloff JL, Herman CE, Jacobs SR, Wieman HL, Wofford JA, Dimascio LN, Ilkayeva O, Kelekar A, Reya T, Rathmell JC. Molecular and cellular biology. 2007 27:4328-39.
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, Cohen GM. Blood. 2009 113:4403-13. (IP)
The Pim kinase pathway contributes to survival signaling in primed CD8+ T cells upon CD27 costimulation. Peperzak V, Veraar EA, Keller AM, Xiao Y, Borst J. Journal of immunology (Baltimore, Md. : 1950). 2010 185:6670-8.
Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. Coloff JL, Mason EF, Altman BJ, Gerriets VA, Liu T, Nichols AN, Zhao Y, Wofford JA, Jacobs SR, Ilkayeva O, Garrison SP, Zambetti GP, Rathmell JC. The Journal of biological chemistry. 2011 286:5921-33.
Hepatitis B virus X protein enhances cisplatin-induced hepatotoxicity via a mechanism involving degradation of Mcl-1. Hu L, Chen L, Li L, Sun H, Yang G, Chang Y, Tu Q, Wu M, Wang H. Journal of virology. 2011 85:3214-28.
A TCR affinity threshold regulates memory CD4 T cell differentiation following vaccination. Baumgartner CK, Yagita H, Malherbe LP. Journal of immunology (Baltimore, Md. : 1950). 2012 189:2309-17.